Indication

Growth failure due to achondroplasia

Growth failure due to achondroplasia is a skeletal manifestation characterized by severely impaired linear bone growth and disproportionate short stature in pediatric patients with open epiphyses. Read more about Growth failure due to achondroplasia

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Growth failure due to achondroplasia therapies.

Showing 1–2 of 2 drugs

VOXZOGO (vosoritide)

BONE FORMATION STIMULATING AGENTS - NATRIURETIC PEPTIDE·GROWTH FAILURE DUE TO ACHONDROPLASIA
BIOMARIN PHARMA

YUVIWEL (navepegritide)

BONE FORMATION STIMULATING AGENTS - NATRIURETIC PEPTIDE·GROWTH FAILURE DUE TO ACHONDROPLASIA
ASCENDIS PHARMA
Filter & compare in the drug finder →Opens the drug finder with Growth failure due to achondroplasia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Growth failure due to achondroplasia.

Growth failure due to achondroplasia is a skeletal manifestation characterized by severely impaired linear bone growth and disproportionate short stature in pediatric patients with open epiphyses.

It is driven by autosomal dominant, gain-of-function mutations in the fibroblast growth factor receptor 3 (*FGFR3*) gene, which lead to constitutive overactivation of downstream intracellular signaling pathways that suppress chondrocyte proliferation and differentiation within the cartilaginous growth plates.

This pathophysiologic cascade disrupts normal endochondral ossification, predominantly impairing long bone elongation.

Clinically, affected individuals present with rhizomelic limb shortening, macrocephaly with frontal bossing, midface hypoplasia, and an increased susceptibility to cervicomedullary compression and spinal stenosis.

Personalize your experience

Follow Growth failure due to achondroplasia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it